<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749446</url>
  </required_header>
  <id_info>
    <org_study_id>ISG-Breast-Sarc</org_study_id>
    <nct_id>NCT04749446</nct_id>
  </id_info>
  <brief_title>Study on Clinical Features and Outcomes of Breast Sarcoma</brief_title>
  <acronym>Breast-Sarc</acronym>
  <official_title>Breast Sarcomas: A Retrospective Analysis of Clinical Features and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Sarcoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Italian Sarcoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multi-institutional retrospective study in order to identify the most relevant&#xD;
      clinical characteristics, treatment strategies, to explore the impact on principal clinical&#xD;
      outcomes and finally, to suggest some principles for management and treatment of breast&#xD;
      sarcomas.&#xD;
&#xD;
      The study will collect data about patients affected by breast sarcoma referred to&#xD;
      participating Institutions between January 2000 and June 2020&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the field of soft tissue sarcomas, breast sarcomas are a truly peculiar family of rare&#xD;
      tumors for both their clinical history and biology of disease.&#xD;
&#xD;
      Surgery (if feasible) is the main therapeutic approach for all the patients with localized&#xD;
      disease, while a pharmacological (chemotherapeutic) and/or radiotherapeutic treatment is&#xD;
      reserved to those with high-risk/recurrent-relapsing/metastatic disease.&#xD;
&#xD;
      Unfortunately, there is a lack of specific prospective trials in breast sarcoma to guide the&#xD;
      clinical decision-making and breast sarcoma patients are often sent to sarcoma referral&#xD;
      centers only after surgery Due to sarcoma-specific clinical features, it is clear that both&#xD;
      diagnostic and clinical strategies mandate a different approach compared to epithelial&#xD;
      tumors. This is of key importance to reach the correct diagnosis, design the best therapeutic&#xD;
      decision-making and subsequent follow-up.&#xD;
&#xD;
      Even if retrospective data limitations and biases, in the lack of prospective data&#xD;
      collection, these data may be a unique and precious source of information For this reasons&#xD;
      this multi-institutional retrospective study is aimed to identify the most relevant clinical&#xD;
      characteristics, treatment strategies, to explore the impact on principal clinical outcomes&#xD;
      and finally, to suggest some principles for management and treatment of breast sarcomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Treatments received for breast sarcoma</measure>
    <time_frame>At diagnosis (baseline) and after 6, 12, 18, 24, 36, 48 and 60 weeks</time_frame>
    <description>To describe treatment that patient diagnosed with breast sarcoma, received</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with primary breast sarcoma</measure>
    <time_frame>Through study inclusion period, an average of 20 years</time_frame>
    <description>Number of patient with a diagnosis of primary breast sarcoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with primary breast sarcoma symptoms</measure>
    <time_frame>Through study inclusion period, an average of 20 years</time_frame>
    <description>Number of patients with primary breast sarcoma symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local-regional Relapse Free Survival (LRFS)</measure>
    <time_frame>Every 3 months (Month 3, Month 6, Month 9...) up to 5 years</time_frame>
    <description>Time elapsed form the treatment (any) start and the onset of Local-regional relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Every 3 months (Month 3, Month 6, Month 9...) up to 5 years</time_frame>
    <description>Time elapsed form the treatment (any) start and the onset of progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>at 5 years</time_frame>
    <description>Time elapsed for the diagnosis to the death for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time of secondary breast sarcoma presentation</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To define the median time to secondary sarcoma presentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of upfront multidisciplinary tumor board consultation</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>To describe the impact of upfront multidisciplinary tumor board consultation on outcomes</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Sarcoma</condition>
  <arm_group>
    <arm_group_label>Breast sarcoma</arm_group_label>
    <description>This cohort include patients affected by breast sarcoma, referred to participating Institutions between January 2000 and June 2020.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Treatment of Breast Sarcoma according clinical practice (includes drugs, surgery or any other received treatments)</intervention_name>
    <description>This observational study collects all the treatments received by the patients according clinical practices or experimental trials and therefore includes drug/biological/surgical and any other applicable treatments&#xD;
Reorder Outcome Measures</description>
    <arm_group_label>Breast sarcoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by breast sarcma referred to participating Institutions between January&#xD;
        2000 and June 2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years at diagnosis&#xD;
&#xD;
          -  primary or secondary breast sarcoma&#xD;
&#xD;
          -  availability of medical data needed for the study (histopathological data, surgery,&#xD;
             chemotherapy, including preceding chemotherapeutic regimens for secondary breast&#xD;
             sarcomas, radiation therapy)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  sarcoma metastases to the breast&#xD;
&#xD;
          -  chest wall sarcomas not arising in the mammary gland&#xD;
&#xD;
          -  cutaneous sarcomas&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Azienda Ospedaliera S. Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Abbondanza Pantaleo, MD</last_name>
      <phone>+39 051 2144043</phone>
      <email>maria.pantaleo@unibo.it</email>
    </contact>
    <investigator>
      <last_name>Maria Abbondanza Pantaleo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso M. De Pas, MD</last_name>
      <phone>+390257489482</phone>
      <email>tommaso.de-pas@ieo.it</email>
    </contact>
    <investigator>
      <last_name>Tommaso M. De Pas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <phone>+390282244540</phone>
      <email>alexia.bertuzzi@cancercenter.humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alexia Bertuzzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <phone>0039091655</phone>
      <phone_ext>4513</phone_ext>
      <email>giuseppebadalamenti@unipa.it</email>
    </contact>
    <contact_backup>
      <last_name>Badalamenti</last_name>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Badalamenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Oncologico - Unit of Medical Oncology</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <zip>33081</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Buonadonna, MD</last_name>
      <email>abuonadonna@cro.it</email>
    </contact>
    <contact_backup>
      <last_name>Angela, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Angela Buonadonna, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia e Dolce</name>
      <address>
        <city>Prato</city>
        <state>PO</state>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <email>ggbaldi@usl4.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo G. Baldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
      <phone>+3902225411123</phone>
      <email>b.vincenzi@unicampus.it</email>
    </contact>
    <investigator>
      <last_name>Bruno Vincenzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCC Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Torino</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
      <phone>39 (011) 993</phone>
      <phone_ext>3623</phone_ext>
      <email>giovanni.grignani@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Grignani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Umberto I</name>
      <address>
        <city>Turin</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoletta Biglia</last_name>
      <phone>039 0115082</phone>
      <phone_ext>682</phone_ext>
      <email>nicoletta.biglia@unito.it</email>
    </contact>
    <investigator>
      <last_name>Nicoletta Biglia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O Ospedali Riuniti Marche Nord</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raffaella Bracci, MD</last_name>
      <phone>039 0721 36</phone>
      <phone_ext>11</phone_ext>
      <email>raffaella.bracci@ospedalimarchenord.it</email>
    </contact>
    <investigator>
      <last_name>Raffaella Bracci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <zip>50100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Gasperoni, MD</last_name>
      <phone>39 055 7949648</phone>
      <email>gasperoni.silvia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Silvia Gasperoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS INT Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <phone>+39022390</phone>
      <phone_ext>2804</phone_ext>
      <email>silvia.stacchiotti@istitutotumori.mi.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Stacchiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena - Unit of Medical Oncology I</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <phone>+390652666</phone>
      <phone_ext>773</phone_ext>
      <email>ferraresi@ifo.it</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Virginia Ferraresi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Città di Torino (Dipartimento di Oncologia)</name>
      <address>
        <city>Torino</city>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonella Boglione, MD</last_name>
      <email>antonella.boglione@aslcittaditorino.it</email>
    </contact>
    <contact_backup>
      <last_name>Boglione, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Antonella Boglione, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Al-Benna S, Poggemann K, Steinau HU, Steinstraesser L. Diagnosis and management of primary breast sarcoma. Breast Cancer Res Treat. 2010 Aug;122(3):619-26. doi: 10.1007/s10549-010-0915-y. Epub 2010 May 18. Review.</citation>
    <PMID>20480227</PMID>
  </reference>
  <reference>
    <citation>Kirova YM, Gambotti L, De Rycke Y, Vilcoq JR, Asselain B, Fourquet A. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):359-63. Epub 2007 Mar 26.</citation>
    <PMID>17379448</PMID>
  </reference>
  <reference>
    <citation>Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1231-7.</citation>
    <PMID>11955733</PMID>
  </reference>
  <reference>
    <citation>Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17(3):405-18. doi: 10.1634/theoncologist.2011-0282. Epub 2012 Feb 14.</citation>
    <PMID>22334455</PMID>
  </reference>
  <reference>
    <citation>Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001 Jul 1;92(1):172-80.</citation>
    <PMID>11443624</PMID>
  </reference>
  <reference>
    <citation>Trent II JC 2nd, Benjamin RS, Valero V. Primary soft tissue sarcoma of the breast. Curr Treat Options Oncol. 2001 Apr;2(2):169-76. Review.</citation>
    <PMID>12057135</PMID>
  </reference>
  <reference>
    <citation>Fields RC, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA. Treatment and outcomes of patients with primary breast sarcoma. Am J Surg. 2008 Oct;196(4):559-61. doi: 10.1016/j.amjsurg.2008.06.010. Epub 2008 Aug 23.</citation>
    <PMID>18723152</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

